Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy

Authors

Anna K. Brady, Washington University School of Medicine in St. Louis
Jonathan D. McNeill, University of Pennsylvania
Brendan Judy, Thomas Jefferson University
Joshua Bauml, University of Pennsylvania
Tracey L. Evans, University of Pennsylvania
Roger B. Cohen, University of Pennsylvania
Corey Langer, University of Pennsylvania
Anil Vachani, University of Pennsylvania
Charu Aggarwal, University of Pennsylvania

Journal

Oncotarget

Publication Date

2015

Volume

6

Issue

30

Inclusive Pages

30287-94

Document Type

Open Access Publication

Rights and Permissions

Brady, A., McNeill, J., Judy, B., Bauml, J., Evans, T., Cohen, R., Langer, C., Vachani, A., & Aggarwal, C. (2015). Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy. Oncotarget, 6(30), 30287-30294. Copyright: © Brady et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Recommended Citation

Brady, Anna K.; McNeill, Jonathan D.; Judy, Brendan; Bauml, Joshua; Evans, Tracey L.; Cohen, Roger B.; Langer, Corey; Vachani, Anil; and Aggarwal, Charu, "Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy." Oncotarget. 6, 30. 30287-94. (2015).
https://digitalcommons.wustl.edu/open_access_pubs/4382